Interest in shares

Hikma Pharmaceuticals Plc
23 March 2007



                   Notification of major interests in shares

LONDON, 23 March 2007 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals group, announces as follows:

1    Identity of the issuer or the underlying issuer of existing    Hikma Pharmaceuticals PLC
     shares to which the voting rights are attached


2    Reason for the notification                                                              Yes/no

     An acquisition or disposal of voting rights

     An acquisition or disposal of financial instruments which may result in the acquisition
     of shares already issues to which voting rights are attached

     An event changing the breakdown of voting rights

     Other (please specify): Compliance with the Transparency Directive                       Yes


3    Full name of the person subject to the notification obligation     Capital Research and Management
                                                                        Company

4    Full name of shareholders if different from above                  -

5    Date of the Transaction (and date on which the threshold crossed   15 March 2007
     is reached differently)

6    Date on which the issuer notified                                  16 March 2007

7    Threshold that is crossed                                          5%

8    Notified details


A. Voting rights attached to shares

Class type of Situation previous to the    Resulting situation after the triggering transaction
shares (if    triggering transaction
possible      Number of    Number of       Number of shares    Number of voting     % of voting
using the     shares       voting rights                       rights               rights
ISIN code)                                 Direct  Indirect    Direct  Indirect     Direct  Indirect

Ordinary      10,223,003   10,223,003              10,223,003          10,223,003           6.0792%
Shares


B. Financial instruments

Resulting situation after the triggering transaction

Type of financial  Expiration Date  Exercise/Conversion       Number of voting rights   % of voting
instrument                          Period/Date               that may be acquired if   rights
                                                              the instrument if
                                                              exercised/converted
N/A


Total A+B

Number of Voting rights                              % of voting rights
10,223,003                                           6.0792%


9    Chain of controlled undertakings through which the voting rights and/or the financial instruments are
     effectively held, if applicable
     N/A


Proxy Voting

10   Name of the proxy holder

11   Number of voting rights proxy holder will
     cease to hold

12   Date on which proxy holder will cease to hold
     voting rights



Additional Information

13   Contact name

14   Contact telephone number





                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Henry Knowles                                    [phone]
Company Secretary


About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products.  Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals.  Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe.  In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $54.5
million.  For news and other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange